A pyrrole-imidazole polyamide targeting transforming growth factor-β1 inhibits restenosis and preserves endothelialization in the injured artery

Cardiovascular Research

Volumn 81, Issue 4, 2009, Pages 797-804

  Yao, En Hui ^a   Fukuda, Noboru ^a,b   Ueno, Takahiro ^a   Matsuda, Hiroyuki ^b   Nagase, Hiroki ^a,b   Matsumoto, Yoshiaki ^b   Sugiyama, Hiroshi ^c   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Pyrrole imidazole polyamide; Rat; Restenosis; Transforming growth factor 1

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; IMIDAZOLE; LECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; POLYAMIDE; PYRROLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTERY INJURY; ARTICLE; CAROTID ARTERY; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; GENE SILENCING; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS;

ANIMALS; CAROTID ARTERY INJURIES; CAROTID STENOSIS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBRONECTINS; GENE SILENCING; HYPERPLASIA; IMIDAZOLES; MALE; MUSCLE, SMOOTH, VASCULAR; NYLONS; PROMOTER REGIONS, GENETIC; PYRROLES; RATS; RATS, INBRED WKY; RECURRENCE; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; TRANSFORMING GROWTH FACTOR BETA1;

EID: 60149106394     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn355     Document Type: Article

References (39)

1. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506.
2. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-514.
3. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949-1956.
4. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
5. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
6. Iakovou I, Sangiorgi GM, Stankovic G, Corvaja N, Michev I, Chieffo A et al. Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. Am J Cardiol 2004;94:351-354.
7. Werner GS, Emig U, Krack A, Schwarz G, Figulla HR. Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis. Catheter Cardiovasc Interv 2004;63:259-264.
8. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-215.
9. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991;88:904-910.
10. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-/31 is increased in human vascular restenosis lesions. J Clin Invest 1992;90:1582-1592.
11. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-1230.
12. Zhao Y. Transforming growth factor-beta (TGF-beta) type I and type II receptors are both required for TGF-beta-mediated extracellular matrix production in lung fibroblasts. Mol Cell Endocrinol 1999;150:91- 97.
13. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A et al. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000;102:1308-1314.
14. Ando H, Fukuda N, Kotani M, Yokoyama S, Kunimoto S, Matsumoto K et al. Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-h1 mRNA inhibits neointima formation in rat carotid artery after balloon injury. Eur J Pharmacol 2004;483:207-214.
15. Trauger JW, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. Nature 1996;382:559-561.
16. White S, Baird EE, Dervan PB. On the pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides. Chem Biol 1997;4:569-578.
17. Murty MS, Sugiyama H. Biology of N-methylpyrrole-N-methylimidazole hairpin polyamide. Biol Pharm Bull 2004;27:468-474.
18. Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB. Regulation of gene expression by small molecules. Nature 1997;387:202-205.
19. Fujimoto K, Iida H, Kawakami M, Bando T, Tao ZF, Sugiyama H. Sequence-specific protection of plasmid DNA from restriction endonuclease hydrolysis by pyrrole-imidazole-cyclopropapyrroloindole conjugates. Nucleic Acids Res 2002;30:3748-3753.
20. Murty MS, Sugiyama H. Biology of N-methylpyrrole-N-methylimidazole hairpin polyamide. Biol Pharm Bull 2004;27:468-474.
21. Lai YM, Fukuda N, Ueno T, Matsuda H, Saito S, Matsumoto K et al. Synthetic pyrrole-imidazole polyamide inhibits expression of the human transforming growth factor-b1 gene. J Pharmacol Exp Therap 2005;315:571-575.
22. Matsuda H, Fukuda N, Ueno T, Tahira Y, Ayame H, Zhang W et al. Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-b1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol 2006;17:422-432.
23. Bando T, Narita A, Saito I, Sugiyama H. Molecular design of a pyrrole-imidazole hairpin polyamide for effective DNA alkylation. Chemistry 2002;8:4781-4790.
24. Hoof T, Riordan JR, Tummler B. Quantitation of mRNA by the kinetic polymerase chain reaction assay: a tool for monitoring P-glycoprotein expression. Anal Biochem 1991;196:161-169.
25. Fukuda N, Kubo A, Izumi Y, Soma M, Kanmatsuse K. Characteristics and expression of transforming growth factor-β receptor subtypes on vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 1995;13:831-837.
26. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997;811:191-206.
27. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002;22:940-948.
28. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
29. Gupta S, Clarkson MR, Duggan J. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-1399.
30. Oemar BS, Werner A, Garnier JM. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997;95:831-839.
31. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77.
32. Hinagata J, Kakutani M, Fujii T, Naruko T, Inoue N, Fujita Y et al. Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 2006;69:263-271.
33. Eto H, Miyata M, Kume N, Minami M, Itabe H, Orihara K et al. Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. Biochem Biophys Res Commun 2006;341:591-598.
34. Minami M, Kume N, Kataoka H, Morimoto M, Hayashida K, Sawamura T et al. Transforming growth factor-b1 increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem Biophys Res Commun 2000;272:357-361.
35. Takehara K, LeRoy EC, Grotendorst GR. TGF-beta inhibition of endothelial cell proliferation: alteration of EGF binding and EGF induced growth-regulatory (competence) gene expression. Cell 1987;49:415-422.
36. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type b -transforming growth factors: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 1986;138:476-482.
37. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87(Suppl. V):V-51-V-55.
38. Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975;32:339-351.
39. Haudenschild CC, Schwartz SM. Endothelial regeneration, II: restitution of endothelial continuity. Lab Invest 1979;41:407-418.